Sarepta Therapeutics Return On Equity vs. Operating Margin

SRPT Stock  USD 102.86  1.64  1.62%   
Based on Sarepta Therapeutics' profitability indicators, Sarepta Therapeutics is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in April. Profitability indicators assess Sarepta Therapeutics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
0.15397822
Current Value
0.16
Quarterly Volatility
0.53609807
 
Credit Downgrade
 
Yuan Drop
 
Covid
Price To Sales Ratio is likely to drop to 5.77 in 2025. Days Sales Outstanding is likely to drop to 121.58 in 2025. At this time, Sarepta Therapeutics' Net Interest Income is comparatively stable compared to the past year. Change To Netincome is likely to gain to about 453.7 M in 2025, despite the fact that Income Quality is likely to grow to (0.83).
For Sarepta Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sarepta Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sarepta Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sarepta Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sarepta Therapeutics over time as well as its relative position and ranking within its peers.
  

Sarepta Therapeutics' Revenue Breakdown by Earning Segment

Check out World Market Map.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.212
Earnings Share
2.34
Revenue Per Share
20.005
Quarterly Revenue Growth
0.659
Return On Assets
0.0377
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sarepta Therapeutics Operating Margin vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sarepta Therapeutics's current stock value. Our valuation model uses many indicators to compare Sarepta Therapeutics value to that of its competitors to determine the firm's financial worth.
Sarepta Therapeutics is currently regarded as top stock in return on equity category among its peers. It is rated second in operating margin category among its peers reporting about  1.25  of Operating Margin per Return On Equity. At this time, Sarepta Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Sarepta Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Sarepta Operating Margin vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Sarepta Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
0.2
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Sarepta Therapeutics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.25 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Sarepta Operating Margin Comparison

Sarepta Therapeutics is currently under evaluation in operating margin category among its peers.

Sarepta Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sarepta Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sarepta Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sarepta Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Sarepta Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-218 K-228.9 K
Operating Income218.1 M229 M
Income Before Tax260.8 M273.8 M
Total Other Income Expense Net42.7 M44.8 M
Net Income235.2 M247 M
Income Tax Expense25.5 M26.8 M
Net Income From Continuing Ops235.2 M247 M
Non Operating Income Net Other46.9 M49.2 M
Net Loss-633.1 M-601.5 M
Interest Income71.8 M75.4 M
Net Interest Income53.4 M56 M
Change To Netincome432.1 M453.7 M
Net Income Per Share 2.47  2.60 
Income Quality(0.87)(0.83)
Net Income Per E B T 0.90  1.30 

Sarepta Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sarepta Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sarepta Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sarepta Therapeutics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Sarepta Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Use Investing Themes to Complement your Sarepta Therapeutics position

In addition to having Sarepta Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Driverless Cars Thematic Idea Now

Driverless Cars
Driverless Cars Theme
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.